Who is sponsoring NCT00286468?

NCT00286468 is sponsored by Takeda.

What condition does NCT00286468 study?

NCT00286468 studies Diabetes Mellitus.

What drugs are being tested in NCT00286468?

Interventions: Alogliptin and glyburide, Alogliptin and glyburide, Glyburide.

What is the status of NCT00286468?

NCT00286468 is currently COMPLETED.

Last reviewed 2012-02-01 · How we verify

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With a Sulfonylurea in Subjects With Type 2 Diabetes

NCT00286468 Phase 3 COMPLETED Results posted

The purpose of this study is to evaluate the efficacy and safety of alogliptin, once daily (QD), combined with a sulfonylurea in adults with type 2 diabetes mellitus.

Details

Lead sponsor	Takeda
Phase	Phase 3
Status	COMPLETED
Enrolment	500
Start date	2006-04
Completion	2007-06

Conditions

Diabetes Mellitus

Interventions

Alogliptin and glyburide
Alogliptin and glyburide
Glyburide

Primary outcomes

Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 26. — Baseline and Week 26.
The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 26 or final visit and glycosylated hemoglobin collected at baseline.

Countries

United States, Argentina, Australia, Brazil, Chile, Dominican Republic, Guatemala, India, Mexico, Netherlands, New Zealand, Peru, Poland, South Africa, United Kingdom